All-atom models for the non-nucleoside binding site of HIV-1 reverse transcriptase complexed with inhibitors: A 3D QSAR approach

Journal of Medicinal Chemistry

Volumn 39, Issue 8, 1996, Pages 1645-1650

  Gussio, Rick ^a   Pattabiraman, Nagarajan ^a   Zaharevitz, Daniel W ^a   Kellogg, Glen E ^b   Topol, Igor A ^a   Rice, William G ^a   Schaeffer, Catherine A ^a   Erickson, John W ^a,b   Burt, Stanley K ^a  

^a SAIC FREDERICK INC   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 2 METHYL 3 PHENYL 1 ISOINDOLINONE; DELAVIRDINE; DIDANOSINE; DRUG CARRIER; INDOLE DERIVATIVE; L 697593; NEVIRAPINE; NEVIRAPINE DERIVATIVE; NSC 119833; NUCLEOSIDE; NUCLEOSIDE ANALOG; PYRIDONE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UK 129485; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANTIVIRAL AGENTS; BINDING SITES; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; INFORMATION SYSTEMS; MODELS, MOLECULAR; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0029978825     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9508088     Document Type: Article

References (40)

1. Wilde, M. I.; Langtry, H. D. Zidovudine. An update of its pharmacodynamics and pharmacokinetic properties and therapeutic efficacy. Drugs 1993, 46, 515-578.
2. De Clercq, E. HIV-1 specific RT inhibitors: Highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase. Med. Res. Rev. 1993, 13, 229-258.
3. Merluzzi, V. J.; Hargrave, K. D.; Labadia, M.; Grozinger, K.; Skoog, M.; Wu, J. C.; Shih, C.; Eckner, K.; Hattox, S.; Adams, J., Rosehthal, A. S.; Faanes, R.; Eckner, R J.; Koup, R. A.; Sullivan, J. L. Inhibition of HIV-1 Replication by a Nonnucleo-side Reverse Transeriptase Inhibitor. Science 1990, 250, 1411-1413.
4. Koup, R. A.; Brewster, F.; Grob, P.; Sullivan, J. L. Nevirapine synergistieally inhibits HIV-1 replication in combination with zidovudine, interferon or CD4 immunoadhesin. AIDS 1993, 7, 1181-1184.
5. Richraan, D. D.; Harlir, D.: Corbeil, J.; Looney, D.: Ignacio, C.; Spector, S. Á.; Sullivan, J.; Cheeseman, S.; Barringer, K.; Pauletti. D.; et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 1994, 68, 1660-1666.
6. Smerdon, S. J.; Jager, J.; Wang. J.; Kohlstaedt, L. A.; Chirino, A. J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci U.S.A. 1994, 91, 3911-3915.
7. Gussio, R.: Pattabiraman, N.; Kellogg, G. E.; Bhat. T. N.; Collins, J.; Burt, S.; Erickson, J. W. Abstracts of Papers, 208th National Meeting of the American Chemical Society, Washington, D.C., 1994; MEDI 34.
8. Pattabiraman, N.; Gussio, R.; Topol, I.; Burt, S.; Erickson, J. W. Abstracts of Papers, 208th National Meeting of the American Chemical Society, Washington, D.C., 1994; MEDI 33.
9. Terrett, N. K; Bojanic, D.; Merson, J. R.; Stephenson, P. T. Imidazo[2′,3′:6,5]dipyrido[3,2-b:2′,3′-e]-1,4- diazepines: Non-nueleoside HIV-I reverse transcriptase inhibitors with greater enzyme affinity than nevirapine. Bioorg. Med. Chem. Lett. 1992, 2, 1745-1750.
10. Bernstein, F. C.; Koetzle, T. F.; Williams, G. J. B.; Meyer, E. F., Jr.; Brice. M. D.; Rodgers, J. R.; Kennard, O.; Shimanouchi, T.; Tasumi, M. The Protein Data Bank: A Computer-based Archival File for Macromolecular Structures. J. Mol. Biol. 1977, 112, 535-542.
11. Abola, E. E.; Bernstein, F. C.; Bryant, S. F.; Koetzle, T. E.; Weng, J. Protein Data Bank. In Crystallographic Databases -Information Content, Software Systems, Scientific Applications; Allen, F. H., Bergerhoff. G., Sievers, R., Eds.; Data Commission of the International Union of Crystallography: Bonn, 1987; pp 107-132.
12. Mui, P. W.; Jacobsen, S. P.; Hargrove, K. D.; Adam, J. Crystal structure of nevirapine, a non-nucleoside inhibitor of HIV-1 reverse transcriptase and computational alignment with a structural diverse inhibitor. J. Med. Chem. 1992, 35, 201-202.
13. Pearlman, D. A.; Case, D. A.; Caldwell, J. C.; Seibel, G. L.; Singh, U. C.; Weiner, P. W.; Kollman, P. A. AMBER 4.0 (UCSF) Manual, 1991.
14. Maple, J. R.; Thacher, T. S.; Dinur, U.; Hagler, A. T. Biosym force field research results in new technique for the extraction of inter- and intramolecular forces. Chem. Design Automat. News 1990, 5, 5-10.
15. Stuart, D. I.; Ren, J. S., Esnouf, R.; Jones, E. Y.; Ross, C.; Somers, D.; Stammers, D. K. High resolution refined structure of HIV-1 reverse transcriptase-inhibitor complexes: Implications for drug resistance. Presented in the Third International Workshop on HIV drug resistance held in Kauai. Hawaii, August 1994, p 29.
16. Meng, E. C.; Kuntz, I. D.; Abraham, D. J., Kellogg, G. E. Evaluating Docked complexes with the HINT exponential function and empirical atomic hydrophobicities. J Comput.-Aided Mol. Des. 1994, 8, 299-306.
17. Wlodawar, A.; Nachnaan, J.; Gilliland, G. L.; Gallagha, W.; Woodward, C. Structure of form III crystals of bovine pancreatic trypsin inhibitors. J. Mol. Biol. 1989, 198, 469-480.
18. Andzelm, J. W.; Wimmer, E. J. Density functional gaussian-type-orbital approach to molecular geometries, vibrations and rotation energies. J. Chem. Phys. 1992, 96, 1280-1303.
19. In DFT calculations, for small orbital relaxation upon ionization or eiectron attachment, the orbitals associated with the lowest ionization potential and highest electron affinity correspond to the HOMO and LUMO in the traditional MO theory. In this paper, we refer to these orbitals generated by DFT as HOMOs and LUMOs.
20. Schafer, W.; Friebe, W.-G.; Leinert, H.; Mertens, A.; Poll, T.; von der Saal, W.; Zilch, H.; Nuber. B.; Ziegler, M. L. Non-nucleoside inhibitors of HTV-1 reverse transcriptase: Molecular modeling and X-ray structure investigations. J. Med. Chem. 1993, 36, 726-733.
21. McMohan, J. B.; Gulakowski, R. J.; Weislow, O. S.; Schultz, R. J.; Narayanan, V. L.; Clanton, D. J.; Pedemonte, R.; Wassmundt, F. W.; Buckheit, R. W., Jr.; Decker. W. D.; White, E. L.; Bader, J. P.; Boyd, M. R. Diarylsulfones, a new chemical class of nonnueleoside antiviral inhibitors of human immunodeficiency virus type I reverse transcriptase. Antimicrob. Agents Chemother. 1993, 37, 754-760.
22. Pauwels, R.; Andries, K.; Debyser, Z.; Daele, P. V.; Schols, D.; Stoffels, P ; Vreese, K. D.; Woesternborghs, R.; Vandamme, A.-M.; Janssen, C. G. M.; Anne, J.; Cauwenbergh, G.; Desmyter, J.; Heykants, J.; Janssen, M. A. C.; Clercq, E. D.; Janssen, P. A. J Potent and hightly selective human immunodeficiency virus type 1 (HTV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 1711-1715.
23. Milne, G. W. A.; Nieklaus, M. C.; Driscoll, J. S.; Wang, S.; Zaharevitz, D. National Cancer Institute Drug Information System 3D Database J Chem. Inf. Comput. Sci. 1994, 34, 1219-1224.
24. RF.
25. Weislow, O. S.; Kiser, R.; Fine, D. L.; Bader, J.; Shoemaker, R. H.; Boyd, M. R. New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 1989, 81, 577-586.
26. Cushman, M.; Golebiewski, W. M.; McMohan, J. B.; Buckheit, B. W., Jr.; Clanton, D. J.; Weislow, O.; Haugwitz. R. D.; Bader, J.; Graham, L.; Rice, W. G. Design, synthesis, and biological evaluation of cosalane, a novel anti-HIV agent which inhibits multiple features of virus reproduction. J. Med. Chem. 1994, 37, 3040-3050
27. Allen, F. H.; Davies, J. E.; Galloy, J. J.; Johnson, O.; Macrae, C. F.; Mitehell, E. M.; Mitchell, G. F.; Smith, J. M.; Watson, D. G. The development of version 3 and 4 of the Cambridge database system. J. Chem. Inf. Comput. Sci. 1991, 31, 187-204.
28. Chimirri, A.; Grasso, S.; Monforte, A. M.; Monforte, P.; Zappala, M. Anti-HIV agents I. Synthesis and in vitro anti-HIV evaluation of novel 1H,3H-thiazolo[3,4-a]benzimidazoles. II Farmaco 1991, 46, 817-823.
29. Pauwels, R.; Andries, K.; Desmyter, J.; Schols, D.; Kukla, M. J.; Breslin, H. J.; Raeymaecjers, A.; Gelder, J. V.; Woesternborghs, R.; Heykants, J.; Sehellekens, K.; Janssen, M. A. C.; Clercq, E. D.; Janssen, P. A. J. Potent and selective inhibiton of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 1990, 343, 470-474.
30. Maass, G.; Immendoerfer, U.; Koemg, B.; Leser, U.; Mueller, B.; Goody, R.; Pfaff, E. Viral resistance to the thiazolo-iso-indolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antirmcrob. Agents Chemother. 1993, 37, 2612-2617.
31. Mertens, A.; Zilch, H.; Konig, B.; Schafer, W.; Poll, T.; Kampe, W.; Seidel, H.; Leser, U.; Leinert, H. Selective non-nucleoside HTV-1 reverse transcriptase inhibitors. New 2,3-dihydrothiazolo-[2,3-a]isoindol-5 (9bH)-ones and related compounds with anti-HTV-1 activity. J. Med. Chem. 1993, 36, 2526-2535.
32. Baba, M.; Tanaka, H.; De Clercq, E.; Pauwels, R.; Balzarini, J.; Schols, D.; Nakashima, H.; Perno, C.-F.; Walker, R. T.; Miyasaka, T. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem. Biophys. Res. Commun. 1989, 165, 1370-1381.
33. 37
34. Ren, J.; Esnouf, R.; Garman, E.; Somers, D.; Ross, C.; Kirby, C.; Keeling, J.; Darby, G.; Jones, Y.; Stuart, D.; Stammers, D High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nature Struct. Biol. 1995, 2, 293-302.
35. Ding, J.; Das, K.; Moereels, H.; Koymans, L.; Andries, K.; Janssen, P. A. J.; Hughes, S. H.; Arnold, E. Structure of HIV-1 RT/TIBO R86183 complex reveals similarity in the binding of diverse nonucleoside inhibitors. Nature Struct. Biol. 1995, 2, 407-415.
36. Ding, J.; Das, K.; Tantillo, C.; Zhang, W.; Clark. A. D., Jr.; Jessen, S.; Lu, X.; Hsiou, Y.; Jacob-Molina, A.; Andries, K.; Pauwels, R.; Moereels, H.; Koymans, L.; Janssen, P. A. J.; Smith, R. H., Jr.; Koepke, M. K.; Michejda, C J.; Hughes, S. H.; Arnold, E. Structure of HTV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R95845 at 2.8 Å resolution. Structure 1995, 3, 365-379.
37. Ren, J.; Esnouf, E.; Hopkins, A.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure 1995, 3, 915-926.
38. Mellors, J. W.; Larder, B. A.; Schinazi, R. F. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Int. Antiviral News 1995, 3, 8-13.
39. Goldman, M. E.; Nunberg, J. H.; O'Brien, J. A.; Quintero, J. C.; Schleif, W. A.; Fruend, K. F.; Gaul, S. L.; Saari, W. S.; Wai, J. S.; Hoffman, J. M.; Anderson, P. S.; Hupe, D. J.; Emini, E. A.; Stern, A. M. Pyridinone derivatives: Specific human immunodeficiency virus type 1 reverse tranascriptase inhibitors with antiviral activity. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 6863-6867.
40. Romero, D. L.; Busso, M ; Tan, C.-K.; Reusser, F.; Palmer, J. R.; Poppe, S. M.; Aristoff, P. A.; Downey, K. M.; So, A. G.; Renick, L ; Tarpley, W. G. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 8806-8810.